SciSparc

SciSparc experienced a spike-and-retreat pattern during regular trading, opening at $5.150 and reaching an intraday high of $5.155 before sliding to $5.000, closing down 2.91%. The decline was primarily driven by profit-taking following the stock's surge of nearly 194% after the subsidiary NeuroThera Labs received conditional regulatory approval for the acquisition of CliniQuantum. The stock further dropped to $5.000 in after-hours trading. Financially, Q4 2025 revenue fell 34.46% YoY to $856,000, with a net loss widening to $10.723 million and EPS of -$29.3424, reflecting ongoing operational challenges. At $4.87, the stock is 69.16% below its 52-week high of $15.79, though it has gained 247.86% YTD, and trades well below both its 20-day MA ($7.69) and 60-day MA ($6.558), indicating weak technical momentum. However, with a market cap of just ~$2.75 million and a PB of 0.65x, the stock retains some valuation floor.